drugset / Trial / NCT00986557
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
RandomizedOpen-labelSupportive care
Summary
RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce cytomegalovirus infection during the first year after a donor stem cell transplant. PURPOSE: This randomized phase II trial is studying T-lymphocyte infusion to see how well it works compared with standard therapy in treating patients at risk of cytomegalovirus infection after a donor stem cell transplant.
Timeline
- Start
- 2009-09
- Primary completion
- 2013-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | in vitro-treated peripheral blood lymphocyte therapy | Cell therapy | — | — |
| Background | Alemtuzumab | Monoclonal antibody | — | — |
| Background | Foscarnet | Small molecule | — | — |
| Background | Ganciclovir | Small molecule | — | Intravenous |